Skip to main content

Compare Stocks

Date Range: 

 SynlogicGlycoMimeticsProcessa PharmaceuticalsIMARAEvofem Biosciences
SymbolNASDAQ:SYBXNASDAQ:GLYCNASDAQ:PCSANASDAQ:IMRANASDAQ:EVFM
Price Information
Current Price$3.26$2.25$6.21$7.84$1.25
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.71.71.21.41.5
Analysis Score3.53.50.03.53.4
Community Score2.72.75.02.92.7
Dividend Score0.00.00.00.00.0
Ownership Score0.81.70.80.80.8
Earnings & Valuation Score1.30.60.00.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$13.25$13.00N/A$35.00$10.00
% Upside from Price Target306.44% upside477.78% upsideN/A346.43% upside700.00% upside
Trade Information
Market Cap$133.17 million$115.96 million$96.39 million$137.79 million$128.55 million
Beta2.22.46-0.06N/A0.07
Average Volume979,604786,34870,759142,5094,480,289
Sales & Book Value
Annual Revenue$2.22 millionN/AN/AN/AN/A
Price / Sales59.99N/AN/AN/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$4.86 per share$3.56 per share$1.46 per shareN/A$0.33 per share
Price / Book0.67N/AN/AN/AN/A
Profitability
Net Income$-51,370,000.00$-57,890,000.00$-3,360,000.00N/A$-80,030,000.00
EPS($1.70)($1.34)N/AN/A($1.31)
Trailing P/E RatioN/AN/A0.000.00N/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-2,761.83%N/AN/AN/AN/A
Return on Equity (ROE)-41.64%-34.22%-79.69%N/A-259.47%
Return on Assets (ROA)-34.39%-31.43%-53.85%N/A-111.70%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.01%N/AN/A
Current Ratio16.42%14.83%0.14%18.78%1.55%
Quick Ratio16.42%14.83%0.14%18.78%1.51%
Ownership Information
Institutional Ownership Percentage39.53%82.15%N/A64.53%44.84%
Insider Ownership Percentage17.95%26.80%54.60%N/A9.90%
Miscellaneous
Employees72541427147
Shares Outstanding40.85 million51.54 million15.52 million17.58 million102.84 million
Next Earnings Date5/13/2021 (Confirmed)7/30/2021 (Estimated)5/13/2021 (Confirmed)8/13/2021 (Estimated)8/3/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Should Value Hunters Buy Evofem Biosciences Inc. (NASDAQ:EVFM) Stock?Should Value Hunters Buy Evofem Biosciences Inc. (NASDAQ:EVFM) Stock?
stocksregister.com - May 12 at 10:18 AM
Evofem Biosciences Says FDA Grants Fast Track Designation For EVO100 - Quick FactsEvofem Biosciences Says FDA Grants Fast Track Designation For EVO100 - Quick Facts
markets.businessinsider.com - May 12 at 10:18 AM
Evofem Biosciences Receives Fast Track Designation for EVO100 for Prevention of Gonorrhea in WomenEvofem Biosciences Receives Fast Track Designation for EVO100 for Prevention of Gonorrhea in Women
finance.yahoo.com - May 12 at 10:18 AM
Evofem Biosciences (NASDAQ:EVFM) Releases Quarterly  Earnings Results, Misses Estimates By $0.07 EPSEvofem Biosciences (NASDAQ:EVFM) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS
americanbankingnews.com - May 9 at 6:12 PM
Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q1 2021 Results - Earnings Call TranscriptEvofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 6:34 AM
Thinking about buying stock in Epizyme, AMC Entertainment, Evofem Biosciences, Nokia, or Arcutis Biotherapeutics?Thinking about buying stock in Epizyme, AMC Entertainment, Evofem Biosciences, Nokia, or Arcutis Biotherapeutics?
benzinga.com - May 7 at 12:44 PM
Evofem BiosciencesInc. (NASDAQ:EVFM) is down -49.38% year-to-date, but analysts find room for a price rallyEvofem BiosciencesInc. (NASDAQ:EVFM) is down -49.38% year-to-date, but analysts find room for a price rally
stocksregister.com - May 7 at 12:44 PM
Evofem Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate UpdateEvofem Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - May 6 at 4:42 PM
After A -46.47% Fall This Year Is Evofem Biosciences Inc. (NASDAQ:EVFM) A Better Buy Than Others?After A -46.47% Fall This Year Is Evofem Biosciences Inc. (NASDAQ:EVFM) A Better Buy Than Others?
marketingsentinel.com - May 6 at 11:42 AM
Why Evofem Biosciences, Inc. (NASDAQ:EVFM) Stock Might Be A Good InvestmentWhy Evofem Biosciences, Inc. (NASDAQ:EVFM) Stock Might Be A Good Investment
stocksregister.com - May 4 at 8:07 PM
Evofem Biosciences, Inc. (NASDAQ:EVFM) Expected to Post Quarterly Sales of $2.02 MillionEvofem Biosciences, Inc. (NASDAQ:EVFM) Expected to Post Quarterly Sales of $2.02 Million
americanbankingnews.com - May 4 at 5:10 AM
An in-depth look at the Evofem Biosciences Inc. (EVFM) stockAn in-depth look at the Evofem Biosciences Inc. (EVFM) stock
marketingsentinel.com - May 3 at 8:43 AM
Evofem Biosciences, Inc. (NASDAQ:EVFM) Sees Large Growth in Short InterestEvofem Biosciences, Inc. (NASDAQ:EVFM) Sees Large Growth in Short Interest
americanbankingnews.com - May 3 at 1:08 AM
-$0.49 EPS Expected for Evofem Biosciences, Inc. (NASDAQ:EVFM) This Quarter-$0.49 EPS Expected for Evofem Biosciences, Inc. (NASDAQ:EVFM) This Quarter
americanbankingnews.com - May 2 at 4:32 AM
Buying Evofem Biosciences, Inc. (NASDAQ:EVFM)? Here Are Some Things to ConsiderBuying Evofem Biosciences, Inc. (NASDAQ:EVFM)? Here Are Some Things to Consider
stocksregister.com - April 29 at 5:39 PM
Evofem Biosciences, Inc. (NASDAQ:EVFM) Rose 1.4% From Its 52-Week Low; YTD Numbers Fall -40.66% – Here Are Some Things To Keep In MindEvofem Biosciences, Inc. (NASDAQ:EVFM) Rose 1.4% From Its 52-Week Low; YTD Numbers Fall -40.66% – Here Are Some Things To Keep In Mind
marketingsentinel.com - April 29 at 12:38 PM
Evofem Biosciences (EVFM) Scheduled to Post Earnings on ThursdayEvofem Biosciences (EVFM) Scheduled to Post Earnings on Thursday
americanbankingnews.com - April 29 at 4:40 AM
Market Analysts see Evofem Biosciences Inc. [EVFM] gaining to $5. Time to buy?Market Analysts see Evofem Biosciences Inc. [EVFM] gaining to $5. Time to buy?
dbtnews.com - April 28 at 8:36 PM
Evofem Biosciences Announces Presentation of Two New Phexxi Data Sets at the 2021 American College of Obstetricians and Gynecologists Annual MeetingEvofem Biosciences Announces Presentation of Two New Phexxi Data Sets at the 2021 American College of Obstetricians and Gynecologists Annual Meeting
finance.yahoo.com - April 28 at 3:36 PM
Evofem Biosciences, Inc. (NASDAQ:EVFM) Given Average Recommendation of "Buy" by BrokeragesEvofem Biosciences, Inc. (NASDAQ:EVFM) Given Average Recommendation of "Buy" by Brokerages
americanbankingnews.com - April 27 at 6:31 AM
Evofem Biosciences, Inc. (NASDAQ:EVFM) is up 8.76% since its low, and it’s only getting startedEvofem Biosciences, Inc. (NASDAQ:EVFM) is up 8.76% since its low, and it’s only getting started
stocksregister.com - April 26 at 2:38 PM
Evofem Biosciences to Report First Quarter 2021 Results and Provide Corporate Update on Thursday, May 6, 2021Evofem Biosciences to Report First Quarter 2021 Results and Provide Corporate Update on Thursday, May 6, 2021
finance.yahoo.com - April 22 at 8:14 AM
Evofem Biosciences Inc (EVFM)Evofem Biosciences Inc (EVFM)
investing.com - April 18 at 9:04 PM
Small Cap Stock Evofem Biosciences, Inc. (EVFM) is a Overweight – AnalystsSmall Cap Stock Evofem Biosciences, Inc. (EVFM) is a Overweight – Analysts
marketingsentinel.com - April 12 at 12:04 PM
Evofem Biosciences Announces Closing of Public Offering of Common StockEvofem Biosciences Announces Closing of Public Offering of Common Stock
finance.yahoo.com - March 29 at 7:32 PM
DateCompanyBrokerageAction
3/25/2021SynlogicSVB LeerinkBoost Price Target
3/24/2021SynlogicJonestradingInitiated Coverage
1/13/2021SynlogicChardan CapitalBoost Price Target
8/10/2020SynlogicHC WainwrightReiterated Rating
5/10/2020SynlogicOppenheimerReiterated Rating
11/13/2019SynlogicPiper Jaffray CompaniesReiterated Rating
8/21/2019SynlogicCitigroupDowngrade
8/9/2019SynlogicWedbushReiterated Rating
5/3/2021GlycoMimeticsStifel NicolausBoost Price Target
12/8/2020GlycoMimeticsRoth CapitalBoost Price Target
3/27/2020GlycoMimeticsCowenInitiated Coverage
8/5/2019GlycoMimeticsJefferies Financial GroupDowngrade
8/5/2019GlycoMimeticsSunTrust BanksDowngrade
12/8/2020Processa PharmaceuticalsBenchmarkInitiated Coverage
10/28/2020Processa PharmaceuticalsCraig HallumInitiated Coverage
4/26/2021IMARAMorgan StanleyLower Price Target
6/8/2020Evofem BiosciencesPiper SandlerInitiated Coverage
5/31/2020Evofem BiosciencesRoyal Bank of CanadaReiterated Rating
5/22/2020Evofem BiosciencesCantor FitzgeraldReiterated Rating
(Data available from 5/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.